Standard Dosage for Small Cell Lung Cancer
Lurbinectedin (Yondelis) is FDA-approved for metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy. The recommended dose is 3.2 mg/m² administered as a 1-hour intravenous infusion every 21 days.[1][2]
How Dosage is Calculated
Dosage is determined by the patient's body surface area (BSA) in square meters, typically calculated using height and weight via formulas like Mosteller or DuBois. For example, a patient with BSA of 1.8 m² receives 5.76 mg (3.2 × 1.8), rounded per institutional protocols to nearest vial size (vials are 4 mg/8 mL).[1][3]
Dose Adjustments for Toxicity
Reduce dose for adverse events graded by CTCAE criteria:
- Myelosuppression (e.g., ANC <1.0 × 10⁹/L or platelets <75 × 10⁹/L): Delay until recovery to grade 1 or baseline, then reduce to 2.6 mg/m² (first reduction) or 2.0 mg/m² (second).
- Hepatotoxicity (e.g., bilirubin >ULN or AST/ALT >2.5×ULN): Delay and reduce similarly.
- Permanent discontinuation after two dose reductions if severe toxicity recurs.[1][2]
| Event | Grade 3/4 Action | Subsequent Doses |
|-------|------------------|------------------|
| Neutropenia/Thrombocytopenia | Delay; G-CSF if prolonged | 2.6 mg/m², then 2.0 mg/m² |
| Transaminase Increase | Delay if >3×ULN | Reduce by 25-50% |
| CPK Elevation | Monitor; hold if >2.5×ULN | Reduce if persists |
Patient Selection Factors
- Performance Status: ECOG 0-2 required; poor status may preclude use.
- Organ Function: Baseline labs must show adequate bone marrow (ANC ≥1.5 × 10⁹/L, platelets ≥100 × 10⁹/L), liver (bilirubin ≤ULN, AST/ALT ≤2.5×ULN), and renal function (CrCl ≥30 mL/min).
- Comorbidities: Avoid in active hepatitis or uncontrolled effusion; monitor CPK in those at rhabdomyolysis risk.[1][2]
Administration and Supportive Care
Premedicate with antiemetics (e.g., dexamethasone, 5-HT3 antagonist). Infuse over 60 minutes through dedicated line; no routine hydration needed. Prophylactic G-CSF recommended due to neutropenia risk (IMpower133 trial: 37% grade 3/4).[2][4]
Differences from Other Indications or Drugs
Lurbinectedin lacks approval beyond SCLC; investigational doses in trials (e.g., ovarian cancer) range 1.5-7.0 mg flat or BSA-adjusted, but not standard. Compared to topotecan (2.3 mg/m² days 1-5), lurbinectedin uses higher single-dose, less frequent schedule.[4]
[1]: FDA Label for Lurbinectedin (Yondelis)
[2]: NCCN Guidelines: Small Cell Lung Cancer, Version 1.2024
[3]: Lexicomp: Lurbinectedin Dosing
[4]: NEJM: Lurbinectedin in SCLC (Trigo et al., 2020)